Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop

Fig. 2

Cdx1 serves as a transcriptional factor of MUC17. a Luciferase assays using AGS cells transfected with one of three MUC17 promoter fragments with differently sized deletions (FA-FC). b The luciferase activity of the FA fragment in AGS cells transfected with a shRNA targeting CDX1. c The luciferase activity of FA and FB in MKN45 cells transfected with CDX1. d Upper, ChIP assay revealed that interacted CDX1 with the promoter region of MUC17. Lower, ChIP assay indicated knocked-down of CDX1 did not impact the transcriptional state of chromatin by using the antibody against H4 acetylated K5. e Luciferase assay using the FA fragment and its mutant derivatives transfected into AGS cells (left) and MKN45 cells overexpressing CDX1 (right). f EMSA assay confirmed that CDX1 binding to the second motif of the MUC17 promoter. g The expression of MUC17 and CDX1 mRNA detected by qPCR in GC cell lines (left). The correlation between CDX1 and MUC17 expression in GC cell lines (right). Error bars represent ± SD of three experiments (*, P < 0.05; **, P < 0.001)

Back to article page